Ardelyx
Fremont, US · 3 known investors
Ardelyx is a biopharmaceutical company that develops first-in-class medicines for patients with unmet medical needs. It focuses on therapeutic areas including chronic kidney disease with hyperphosphatemia and irritable bowel syndrome with constipation.
Biotech
Founders & leadership
MR
Michael RaabFounder
MK
Mark KaufmannExecutive
EG
Elizabeth GrammerExecutive
DR
David RosenbaumExecutive
JC
Jeremy CaldwellExecutive
MR
Mike Raabin
Board
DM
David MottBoard director
AJ
Annalisa JenkinsBoard director
RR
Richard RodgersBoard director
GR
Gordon RingoldBoard director
PG
Peter G. SchultzBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$187.8M disclosed across 2 rounds · 2015–2016
▶$110MraisedAug 2016 · 31 investors · PharmaceuticalsRule 506(b)
▶$110MraisedAug 2016 · 31 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Annalisa JenkinsDirector
- Paul KornerExecutive Officer
- David MottDirector
- David RosenbaumExecutive Officer
- Elizabeth GrammerExecutive Officer
- Michael RaabExecutive Officer, Director
- Gordon RingoldDirector
- Robert BazemoreDirector
- Richard RodgersDirector
- Jeff JacobsExecutive Officer
- Mark KaufmannExecutive Officer
- William Bertrand, Jr.Director
- Jeremy CaldwellExecutive Officer
- Offering amount
- $110M
- Amount sold
- $110M
- First sale
- Jul 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$77.8MraisedJun 2015 · 11 investors · PharmaceuticalsRule 506(b)
▶$77.8MraisedJun 2015 · 11 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Annalisa JenkinsDirector
- Mark KaufmannExecutive Officer
- Elizabeth GrammerExecutive Officer
- Richard RodgersDirector
- Gordon RingoldDirector
- Peter G. SchultzDirector
- David MottDirector
- David RosenbaumExecutive Officer
- Jeremy CaldwellExecutive Officer
- Michael RaabExecutive Officer, Director
- Offering amount
- $108M
- Amount sold
- $77.8M
- Sales commissions
- $2.5M
- Placement agents
- Leerink Partners LLC
- First sale
- Jun 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Ardelyx do?
- Ardelyx is a biopharmaceutical company that develops first-in-class medicines for patients with unmet medical needs. It focuses on therapeutic areas including chronic kidney disease with hyperphosphatemia and irritable bowel syndrome with constipation.
- Who founded Ardelyx?
- Ardelyx was founded by Michael Raab.
- Who are Ardelyx's investors?
- Ardelyx's investors include Foresite Capital, HEALTHCARE ROYALTY PARTNERS, New Enterprise Associates (NEA).
- How much funding has Ardelyx raised?
- Ardelyx has disclosed $187.8M raised across 2 rounds.
- Where is Ardelyx headquartered?
- Ardelyx is headquartered in Fremont, US.